EUVIMEDEUVIMED entdecken
LeserbriefKommentarMetaanalyse

Letter Re: A meta-analysis of efficacy and safety data from head-to-head first-line trials of epidermal growth factor receptor inhibitors versus bevacizumab in adult patients with RAS wild-type metastatic colorectal cancer by sidedness

Pei Zhang, Yihui Han, Zhaolun Cai, Dan Cao

European Journal of Cancer · 2024

DOI: 10.1016/j.ejca.2024.114266 ↗

Kurz gefasst

Leserbrief in der Zeitschrift European Journal of Cancer, 2024. Verfasst von Pei Zhang und 3 weiteren Autor:innen. Beteiligte Einrichtung: Division of Abdominal Tumor Multimodality Treatment, Cancer Center, West China Hospital, Sichuan University, No.37 Guoxue Alley, Chengdu 610041, Sich…. Hauptthemen laut MEDLINE: Bevacizumab, Colorectal Neoplasms, ErbB Receptors. Die Arbeit nennt 8 Literaturangaben. Gefördert von: Sichuan University, Sichuan University West China Hospital.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

BevacizumabColorectal NeoplasmsErbB ReceptorsAdultHumansAntineoplastic Agents, ImmunologicalMeta-Analysis as TopicNeoplasm MetastasisRandomized Controlled Trials as Topic

Substanzen

Antineoplastic Agents, ImmunologicalBevacizumabEGFR protein, humanErbB Receptors

Autor:innen und Institutionen

  • Division of Abdominal Tumor Multimodality Treatment, Cancer Center, West China Hospital, Sichuan University, No.37 Guoxue Alley, Chengdu 610041, Sichuan, China.
  • Gastric Cancer Center, West China Hospital, Sichuan University, Chengdu 610041, Sichuan, China; Department of General Surgery, West China Hospital, Sichuan University, Chengdu, China.
  • Division of Abdominal Tumor Multimodality Treatment, Cancer Center, West China Hospital, Sichuan University, No.37 Guoxue Alley, Chengdu 610041, Sichuan, China. Electronic address: caodan@scu.edu.cn.

Förderung

  • Sichuan University
  • Sichuan University West China Hospital

Zitieren

APA

Zhang, P., Han, Y., Cai, Z., & Cao, D. (2024). Letter Re: A meta-analysis of efficacy and safety data from head-to-head first-line trials of epidermal growth factor receptor inhibitors versus bevacizumab in adult patients with RAS wild-type metastatic colorectal cancer by sidedness. European Journal of Cancer. https://doi.org/10.1016/j.ejca.2024.114266

Vancouver

Zhang P, Han Y, Cai Z, Cao D. Letter Re: A meta-analysis of efficacy and safety data from head-to-head first-line trials of epidermal growth factor receptor inhibitors versus bevacizumab in adult patients with RAS wild-type metastatic colorectal cancer by sidedness. European Journal of Cancer. 2024. doi:10.1016/j.ejca.2024.114266

BibTeX
@article{Zhang2024,
  author = {Zhang, Pei and Han, Yihui and Cai, Zhaolun and Cao, Dan},
  title = {Letter Re: A meta-analysis of efficacy and safety data from head-to-head first-line trials of epidermal growth factor receptor inhibitors versus bevacizumab in adult patients with RAS wild-type metastatic colorectal cancer by sidedness},
  journal = {European Journal of Cancer},
  year = {2024},
  doi = {10.1016/j.ejca.2024.114266}
}
Kostenlos starten →